权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Microbiome-microglia interactions in Alzheimer’s disease pathophysiology

阿尔茨海默病病理生理学中微生物组与小胶质细胞的相互作用

基本信息

批准号：
10679850
负责人：
Lisa Blackmer-Raynolds
金额：
$ 4.77万
依托单位：
EMORY UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-05-03 至 2025-05-02
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10679850
关键词：
Acceleration Affect Alzheimer like pathology Alzheimer&apos s Disease Alzheimer&apos s disease model Alzheimer&apos s disease pathology Alzheimer&apos s disease patient Amyloid Amyloid beta-Protein Bacteria Bacteroidaceae Bacteroides thetaiotaomicron Behavioral Brain Brain Pathology Caregivers Cell Communication Cells Clinical Trials Cognition Cognitive Communication Data Data Set Dementia Development Disease Disease Outcome Disease Progression Enterobacteriaceae Escherichia coli Etiology Failure Functional disorder Gene Expression Genetic Transcription Germ-Free Gnotobiotic Health Immune Immune signaling Impaired cognition Individual Inflammation Inflammatory Inflammatory Response Lactobacillus Link Macrophage Mediating Microbe Microglia Modeling Molecular Biology Mus National Research Service Awards Nervous System Physiology Neuroimmune Neurons Neurosciences Outcome Pathologic Pathology Pathway interactions Patients Peripheral Persons Phagocytes Public Health Research Risk Factors Role Shapes Signal Transduction Symptoms System Techniques Testing Time Tissues Training United States Wild Type Mouse abeta accumulation career cell type cytokine disorder risk dysbiosis functional outcomes gut bacteria gut dysbiosis gut microbes gut microbiome immunoregulation improved inflammatory modulation innovation insight interdisciplinary approach microbial microbial colonization microbiome microbiome composition monocyte mouse model mutant neuroinflammation neuropathology neurotoxicity neurotransmission novel pharmacologic response single nucleus RNA-sequencing stem tau Proteins therapeutically effective transcriptomics transmission process

项目摘要

Project Summary: Alzheimer’s disease (AD) is a growing public health threat that places an immense burden on patients, caregivers, and the economy. Despite a century of research and over 2,000 clinical trials, AD has limited treatment options and no cure. The failure to develop effective therapeutics likely stems from an incomplete understanding of AD etiology—highlighting the crucial need to identify and better understand modifiable disease risk factors. Recent evidence suggests that, in addition to brain pathology, AD patients also display alterations in the gut microbiome that may contribute to disease. Manipulation of the gut microbiome is sufficient to improve or exacerbate AD-like symptoms and pathology in mouse models, suggesting that the microbiome may directly contribute to disease development and progression. The mechanism by which the microbiome impacts disease etiology is currently unknown, however, one possibility is through modulation of inflammatory responses. The gut microbiome has been shown to influence the development and activation states of both peripheral and brain- resident immune cells that are critical for amyloid clearance and neuronal health. However, the contribution of individual AD-associated microbial species to neuroinflammatory and disease outcomes is unknown, and the mechanisms of this gut-to-brain communication have yet to be explored. The present NRSA will address this gap, determining the consequences of, and mechanisms by which, specific AD-associated gut microbes shape neuroinflammatory and disease outcomes. Aim 1 will establish the effects of individual AD-associated gut microbes on microglia functional state and response to stimulation (1.1). Furthermore, it will determine whether these gut-to-brain signals are mediated by specific peripheral immune signals triggered by discrete bacterial molecules (1.2). Aim 2 will concurrently determine the pathophysiological impacts of specific AD-associated bacteria on disease outcomes (2.1) and evaluate whether microglia and specific bacterial inflammogens are necessary for these effects. This innovative, interdisciplinary approach will provide key mechanistic links between gut dysbiosis and AD outcomes. In addition, by identifying both microbe and host-derived cellular pathways that impact disease state, it will identify novel and specific treatment targets for AD.

项目总结: